Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Growth Metrics
Income Statement
Others
Ratios

Cresco Labs (CRLBF) Cash & Equivalents (2019 - 2025)

Cresco Labs' Cash & Equivalents history spans 7 years, with the latest figure at $57.9 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 57.91% year-over-year to $57.9 million; the TTM value through Dec 2025 reached $57.9 million, down 57.91%, while the annual FY2025 figure was $57.9 million, 57.91% down from the prior year.
  • Cash & Equivalents reached $57.9 million in Q4 2025 per CRLBF's latest filing, down from $137.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $223.5 million in Q4 2021 to a low of $57.9 million in Q4 2025.
  • Average Cash & Equivalents over 5 years is $128.4 million, with a median of $119.3 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: soared 63.96% in 2021, then crashed 57.91% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $223.5 million in 2021, then crashed by 46.61% to $119.3 million in 2022, then fell by 13.33% to $103.4 million in 2023, then surged by 33.0% to $137.6 million in 2024, then plummeted by 57.91% to $57.9 million in 2025.
  • Per Business Quant, the three most recent readings for CRLBF's Cash & Equivalents are $57.9 million (Q4 2025), $137.6 million (Q4 2024), and $103.4 million (Q4 2023).